# Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

> **NCT03835533** · PHASE1 · COMPLETED · sponsor: **Parker Institute for Cancer Immunotherapy** · enrollment: 43 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** NKTR-214 (Cohort A)
- **DRUG:** Nivolumab (Cohort A, B and C)
- **RADIATION:** Stereotactic body radiation therapy (SBRT) (Cohort B)
- **DRUG:** CDX-301 (Cohort B and C)
- **DRUG:** Poly-ICLC (Cohort B)
- **DRUG:** INO-5151 (Cohort C)
- **DEVICE:** Cellectra 2000

## Key facts

- **NCT ID:** NCT03835533
- **Lead sponsor:** Parker Institute for Cancer Immunotherapy
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-21
- **Primary completion:** 2022-10-03
- **Final completion:** 2022-10-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-04-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03835533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03835533, "Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03835533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*